Something to note: oral treatment & if successful:
https://www.google.com.au/amp/s/www.nytimes.com/2021/10/17/health/covid-treatment-access-molnupiravir.amp.html
3% vaccination rate across Africa, quoted in this article. That’s appalling. Oral treatments for COVID-19 should know no boundaries. They don’t need cold-chain nor expense or expertise to hospitals administering IV expensive MABS. Other Drug companies (ie Merck) will allow out-licensing with cheaper cost to Govts/patients for oral antivirals +/- WHO support.
https://www.reuters.com/business/healthcare-pharmaceuticals/aurobindo-pharma-stop-molnupiravir-trial-moderate-covid-19-patients-2021-10-08/
Interesting article above on Molnupiravir trials in India.
GLTAH
DXB Chart, page-118
-
- There are more pages in this discussion • 1,310 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $214.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 39.0¢ | 37.0¢ | $503.5K | 1.322M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 26318 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 170072 | 6 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |